- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Digirad readies solid-state camera
Solid-state digital gamma camera developer Digirad next week will display a completed prototype of its Notebook Imager system for the first time at a Society of Nuclear Medicine meeting, according to Karen Klause, president and CEO of the San Diego
Solid-state digital gamma camera developer Digirad next week will display a completed prototype of its Notebook Imager system for the first time at a Society of Nuclear Medicine meeting, according to Karen Klause, president and CEO of the San Diego company. Digirad several months ago filed for 510(k) clearance of the system, which, if cleared, will be the first solid-state digital gamma camera on the market.
Digirad will show a wide range of clinical images collected with Notebook Imager, including bone, cardiac, liver, and thyroid scans. Notebook Imager is capable of the same range of applications as a standard gamma camera, with the exception of whole-body bone scans, which must be acquired a section at a time, due to the camera's small field-of-view. In addition, SPECT studies are conducted with patients seated in a rotating chair.
Digirad has been building a production capacity for the systems, and is also hiring a sales force to market the cameras directly in the U.S. The company is open to OEM relationships for distribution of Notebook Imager in international markets, Klause said.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
